QLT's eye drug gets orphan designation in U.S.
(Reuters) - Canadian biotechnology company QLT Inc said the U.S. health regulator granted an orphan status to its key Eye drug. The drug, Visudyne, is already approved as a treatment for age-related macular degeneration, a cause of blindness in people over the age of 55, and the company is now seeking approval for chronic or recurrent central serous chorioretinopathy (CSC). CSC symptoms include blind spots in the central visual field, reduced contrast sensitivity and color vision. Orphan drug designation is granted by the U.S. ... read more..
source:http://yhoo.it/zg7rA7
No comments:
Post a Comment